Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07587762

Predicting the Clinical Advantages of Speaking Valves Through Wearable Devices

The population included in this study consists of tracheostomy patients admitted to the pulmonary department of Beijing Rehabilitation Hospital, undergoing decannulation rehabilitation treatment. Once patient conditions stabilized, they were all transitioned to the decannulation process established by our department in 2018, which utilizes a speaking valve instead of capping.The initial duration for the patient to wear the speaking valve is 30 minutes.The monitoring period for wearable devices is from 1 hour before the initial use of the speaking valve to 1 hour after its removal.Monitored for a total of 2 hours and 30 minutes.Explore the clinical benefits of the speaking valve by comparing the changes in patients' physiological parameters and clinical index metrics before and after using the speaking valve.

Criteria for the successful use of the speaking valve for 30 minutes:

1. Breathing is steady at rest: no apparent dyspnea, chest tightness, or orthopnea, etc. 2. Heart rate, blood pressure, and SpO₂ are all stable overall.SpO₂ reduction from baseline < 5%. 3. No frequent need for emergency sputum suction or indications of sputum blockage while wearing it.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Physiological Parameter Tracheostomy Wearable Devices

Age range

18 year–90 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Beijing Rehabilitation Hospital, Capital Medical University

Beijing, Beijing Municipality, 100144, China

Location status: Recruiting

Location contact

光宇 牛

CONTACT

[email protected]

86-13681210212

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • 90 years≥Age≥18 years;
  • Tracheotomy post-operation>48 hours；
  • Weaned off mechanical ventilation;
  • Clinically stable condition;
  • Tolerable for cuff deflation;
  • Able to tolerate wearing a speaking valve continuously for 30 minutes;
  • Signed informed consent.

Exclusion criteria

  • Patients with abnormal skin conditions preventing continuous wearing of monitoring devices;
  • Inability to tolerate wearing a speaking valve continuously for 30 minutes;
  • Interruption of physiological monitoring data;
  • Poor quality of physiological monitoring data;
  • Recently underwent neck/upper airway surgery (≤48 hours, to avoid airflow impact on the upper airway);
  • Severe consciousness disturbance/delirium (RASS score≤-3 or ≥ +2), extreme anxiety/uncooperativeness;
  • Total laryngectomy or laryngotracheal separation;
  • Age <18 years or >90 years;
  • Malignant tumor with an expected survival time ≤6 months;
  • The patient or legal representative is unable to sign the informed consent form.

Treatment and study plan

Tracheostomy patients who are able to tolerate wearing a speaking valve for 30 minutes

Other

Once patient conditions stabilized, they were all transitioned to the decannulation process established by our department in 2018, which utilizes a speaking valve instead of capping.The initial duration for the patient to wear the speaking valve is 30 minutes.If the patient can tolerate wearing the speaking valve for 30 minutes, they fulfill the inclusion criteria.The monitoring period for wearable devices is from 1 hour before the initial use of the speaking valve to 1 hour after its removal.Monitored for a total of 2 hours and 30 minutes.

Physiological parameters recorded prior to wearing the speaking valve served as the baseline.Compare the physiological parameters while wearing the speaking valve and after its removal to investigate the clinical benefits that the speaking valve can provide.To promote the application of speaking valves in future clinical work more effectively

Primary outcomes

  1. degree of change in oxygen saturation（%）

    Time frame: Using wearable biosensors, high-resolution physiological data were continuously collected during three phases: baseline (30 minutes), speaking valve placement period (30 minutes), and recovery period (30 minutes after speaking valve removal).

    Previous studies have been concerned that speaking valve placement increases upper airway resistance, thereby inducing dyspnea and hypoxemia in patients. Therefore, we used continuous wearable physiological monitoring devices to observe changes in oxygen saturation before, during, and after the training.

  2. Temporal rate of change of asymmetric cardiovascular responses and delayed autonomic recovery（percentage change from baseline）

    Time frame: 30 minutes before speaking valve placement, throughout the entire training session (i.e., during valve wear), and 30 minutes after the training session

    The rate of change (percentage per minute) in asymmetric cardiovascular responses (e.g., heart rate variability indices) and delayed autonomic recovery will be calculated. Physiological data (heart rate, HRV metrics) are continuously collected before, during, and after speaking valve placement. The primary reported value is the slope of change over time, expressed as a percentage relative to baseline, aggregated across all participants using mixed-effects modeling to produce a single mean rate of change

  3. Rate of respiratory phase variation during training（percentage change in phase duration）

    Time frame: 30 minutes before speaking valve placement, throughout the entire training session (i.e., during valve wear), and 30 minutes after the training session

    The rate of change in respiratory phase variation (e.g., changes in inspiratory/expiratory time proportion) during speaking valve training. Respiratory parameters are continuously recorded. The outcome is the calculated rate of change (percentage per minute) from baseline to the active training period and to the recovery period. A single aggregated value (mean slope) will be derived from all participants using linear mixed models.

Study contacts

Contact information is provided by the study sponsor or research team.

Bin Zhang

CONTACT

[email protected]

+8618600530758

Hongying Jiang

CONTACT

[email protected]

+8601056981555

Sponsors and collaborators

Lead sponsor

Bin Zhang

Other

Collaborators

  • Capital Medical University
  • Chinese PLA General Hospital

Registry information

Official study title

Predicting the Clinical Advantages of Speaking Valves Through Wearable Devices:A Prospective Cohort Study

Important dates

Study start
2026
Primary completion
2026
Study completion
2026
First posted
May 14, 2026
Registry last updated
May 14, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.